Log In
Saturday 15th June 2019

Gastrointestinal cancer drug shows promise

4th April 2012

Bayer has said that its cancer drug has improved chances of survival in patients suffering from a type of gastrointestinal tumour and kept the condition from worsening, following a 199-patient late-stage trial.

Findings showed that a combination of Bayer’s tumour-fighting drug regorafenib and best supportive care prolonged survival in patients with metastatic gastrointestinal stromal tumours or GIST, when compared with a dummy drug and best supportive care. Bayer now plans to file for US approval for regorafenib to treat metastatic GIST.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2019